View Past PerformanceNeutra 대차대조표 건전성재무 건전성 기준 점검 0/6Neutra 의 상태를 파악하기에는 데이터가 부족합니다.핵심 정보n/a부채/자본 비율n/a부채이자보상배율n/a현금n/a자본n/a총부채n/a총자산n/a최근 재무 건전성 업데이트공고 • Dec 13Neutra Corp. Files Form 15Neutra Corp. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common stock under the Securities Exchange Act of 1934, as amended.공고 • Jun 18Neutra Corp. announced delayed 10-Q filingOn 06/17/2024, Neutra Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공고 • May 01Neutra Corp. announced delayed annual 10-K filingOn 04/30/2024, Neutra Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공고 • Jun 15Neutra Corp. announced delayed 10-Q filingOn 06/14/2023, Neutra Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공고 • Jun 15Neutra Corp. announced delayed 10-Q filingOn 06/14/2022, Neutra Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공고 • May 03Neutra Corp. announced delayed annual 10-K filingOn 05/02/2022, Neutra Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.모든 업데이트 보기Recent updates실시간 뉴스 • Jun 30Neutra Expands Clinical Trial Portfolio With New Women’s Health Joint Venture and ContractsNeutra’s subsidiary Neutra Life Sciences entered a joint venture with Women’s Healthcare Center of Baytown, adding a dedicated women’s health site to its clinical trial network and securing new contracts across Oncology, Dermatology, Pulmonology and Women’s Health. Management says the expanded portfolio and additional sponsor agreements give Neutra Life Sciences a wider base of trials and partners to work with through 2026, which could influence how revenue is spread across therapeutic areas and customers. Neutra’s stock last traded at $0.00, with the share price down 33.3% over the past week, highlighting ongoing volatility around a very low-priced OTC stock. The key investor angle is execution: the value of this wider trial footprint will depend on how efficiently Neutra converts these new contracts into completed studies and repeat business from sponsors.공고 • Dec 13Neutra Corp. Files Form 15Neutra Corp. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common stock under the Securities Exchange Act of 1934, as amended.공고 • Jun 18Neutra Corp. announced delayed 10-Q filingOn 06/17/2024, Neutra Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공고 • May 01Neutra Corp. announced delayed annual 10-K filingOn 04/30/2024, Neutra Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공고 • Jun 15Neutra Corp. announced delayed 10-Q filingOn 06/14/2023, Neutra Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공고 • Jan 31Neutra Corp. (OTCPK:NTRR) executed a binding letter of intent to acquire Mercury Clinical Research, Inc.Neutra Corp. (OTCPK:NTRR) executed a binding letter of intent to acquire Mercury Clinical Research, Inc. on January 30, 2023. The parties intend to enter into a binding agreement within the next 90 days. Neutra expects to fund the acquisition with a combination of cash and equity to provide the Company with the optimum financial flexibility in the future. Mercury will become a wholly owned subsidiary of the Company and is expected to place executives in senior management positions. Transaction is subject to customary conditions, including but not limited to the following key conditions: Execution of the Definitive Agreement, Completion of mutually satisfactory due diligence and receipt of all required regulatory, corporate and third party approvals. Transaction is expected to close in third quarter of 2023.공고 • Jun 15Neutra Corp. announced delayed 10-Q filingOn 06/14/2022, Neutra Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공고 • May 03Neutra Corp. announced delayed annual 10-K filingOn 05/02/2022, Neutra Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공고 • Jun 25Neutra Corp. (OTCPK:NTRR) acquired Deity Wellness.Neutra Corp. (OTCPK:NTRR) acquired Deity Wellness on June 23, 2021. Neutra Corp. (OTCPK:NTRR) completed the acquisition of Deity Wellness on June 23, 2021.공고 • Jun 15Neutra Corp. announced delayed 10-Q filingOn 06/14/2021, Neutra Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공고 • May 04Neutra Corp. announced delayed annual 10-K filingOn 05/03/2021, Neutra Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공고 • Dec 18Neutra Corp. announced delayed 10-Q filingOn 12/16/2020, Neutra Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.재무 상태 분석단기부채: NTRR 의 단기 자산이 단기 부채를 감당하는지 판단하기에는 데이터가 부족합니다.장기 부채: NTRR의 단기 자산이 장기 부채를 충당하는지 판단하기에 데이터가 부족합니다.부채/자본 비율 추이 및 분석부채 수준: satisfactory인지 판단하기 위해 NTRR 의 순 부채 대 자기자본 비율을 계산하기에는 데이터가 부족합니다.부채 감소: 지난 5년 동안 NTRR의 부채 대비 자본 비율이 감소했는지 판단하기에 데이터가 부족합니다.부채 범위: NTRR 의 부채가 영업 현금 흐름에 의해 잘 충당되었는지 판단하기에는 데이터가 부족합니다.이자 보장: NTRR 의 부채에 대한 이자 지급이 EBIT에 의해 잘 충당되었는지 판단할 데이터가 부족합니다.대차대조표건전한 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 건실한 기업.View Dividend기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/16 03:56종가2026/07/16 00:00수익2024/04/30연간 수익2024/01/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Neutra Corp.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공고 • Dec 13Neutra Corp. Files Form 15Neutra Corp. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common stock under the Securities Exchange Act of 1934, as amended.
공고 • Jun 18Neutra Corp. announced delayed 10-Q filingOn 06/17/2024, Neutra Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공고 • May 01Neutra Corp. announced delayed annual 10-K filingOn 04/30/2024, Neutra Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공고 • Jun 15Neutra Corp. announced delayed 10-Q filingOn 06/14/2023, Neutra Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공고 • Jun 15Neutra Corp. announced delayed 10-Q filingOn 06/14/2022, Neutra Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공고 • May 03Neutra Corp. announced delayed annual 10-K filingOn 05/02/2022, Neutra Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
실시간 뉴스 • Jun 30Neutra Expands Clinical Trial Portfolio With New Women’s Health Joint Venture and ContractsNeutra’s subsidiary Neutra Life Sciences entered a joint venture with Women’s Healthcare Center of Baytown, adding a dedicated women’s health site to its clinical trial network and securing new contracts across Oncology, Dermatology, Pulmonology and Women’s Health. Management says the expanded portfolio and additional sponsor agreements give Neutra Life Sciences a wider base of trials and partners to work with through 2026, which could influence how revenue is spread across therapeutic areas and customers. Neutra’s stock last traded at $0.00, with the share price down 33.3% over the past week, highlighting ongoing volatility around a very low-priced OTC stock. The key investor angle is execution: the value of this wider trial footprint will depend on how efficiently Neutra converts these new contracts into completed studies and repeat business from sponsors.
공고 • Dec 13Neutra Corp. Files Form 15Neutra Corp. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common stock under the Securities Exchange Act of 1934, as amended.
공고 • Jun 18Neutra Corp. announced delayed 10-Q filingOn 06/17/2024, Neutra Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공고 • May 01Neutra Corp. announced delayed annual 10-K filingOn 04/30/2024, Neutra Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공고 • Jun 15Neutra Corp. announced delayed 10-Q filingOn 06/14/2023, Neutra Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공고 • Jan 31Neutra Corp. (OTCPK:NTRR) executed a binding letter of intent to acquire Mercury Clinical Research, Inc.Neutra Corp. (OTCPK:NTRR) executed a binding letter of intent to acquire Mercury Clinical Research, Inc. on January 30, 2023. The parties intend to enter into a binding agreement within the next 90 days. Neutra expects to fund the acquisition with a combination of cash and equity to provide the Company with the optimum financial flexibility in the future. Mercury will become a wholly owned subsidiary of the Company and is expected to place executives in senior management positions. Transaction is subject to customary conditions, including but not limited to the following key conditions: Execution of the Definitive Agreement, Completion of mutually satisfactory due diligence and receipt of all required regulatory, corporate and third party approvals. Transaction is expected to close in third quarter of 2023.
공고 • Jun 15Neutra Corp. announced delayed 10-Q filingOn 06/14/2022, Neutra Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공고 • May 03Neutra Corp. announced delayed annual 10-K filingOn 05/02/2022, Neutra Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공고 • Jun 25Neutra Corp. (OTCPK:NTRR) acquired Deity Wellness.Neutra Corp. (OTCPK:NTRR) acquired Deity Wellness on June 23, 2021. Neutra Corp. (OTCPK:NTRR) completed the acquisition of Deity Wellness on June 23, 2021.
공고 • Jun 15Neutra Corp. announced delayed 10-Q filingOn 06/14/2021, Neutra Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공고 • May 04Neutra Corp. announced delayed annual 10-K filingOn 05/03/2021, Neutra Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공고 • Dec 18Neutra Corp. announced delayed 10-Q filingOn 12/16/2020, Neutra Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.